What are the indications for Aprexitentan (Tryvio)? Suitable for patients with high blood pressure

Aprocitentan-Tryvio is a novel endothelin receptor antagonist developed to treat patients with refractory or poorly controlled hypertension. Traditional antihypertensive drugs, such as diuretics, calcium channel blockers, β-blockers, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), may be difficult to achieve stable blood pressure control in some patients. For this high-risk group, the emergence of aprecitentan provides a new treatment idea.

Its main indication is the treatment of essential hypertension in adult patients in combination with other antihypertensive drugs. By lowering blood pressure levels, aprecitentan helps reduce the risk of cardiovascular and cerebrovascular events, such as stroke, myocardial infarction, and heart failure. These diseases are the leading causes of death and disability worldwide, so the significance of blood pressure management is not only to control readings, but also to improve the health of the cardiovascular system in the long term.

Patient groups that are particularly suitable for the use of aprecitentan include: patients with refractory hypertension who have been unable to lower their blood pressure to the ideal range after long-term use of three or more conventional antihypertensive drugs; patients with cardiovascular risk factors, such as patients with diabetes, obesity or chronic kidney disease, who are more dependent on blood pressure control; and patients who have poor tolerance to traditional drugs or who have difficulty continuing to take medication due to side effects.

In addition, aprecitentan is effective when combined with other antihypertensive drugs. Due to its different action targets, it can further improve the vasodilation ability on the basis of traditional drugs, thereby achieving dual control of blood pressure. With the trend of gradually updating guideline recommendations, aprecitentan is expected to become an important part of the combined treatment of hypertension in the future. It should be noted that not all patients are suitable for this drug. Its use is not currently recommended for patients with moderately or severely impaired liver function.

Reference materials:https://go.drugbank.com/drugs/DB15059